217 related articles for article (PubMed ID: 29670075)
21. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
[TBL] [Abstract][Full Text] [Related]
22. SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis.
Schüler S; Diersch S; Hamacher R; Schmid RM; Saur D; Schneider G
Int J Oncol; 2011 Jan; 38(1):219-25. PubMed ID: 21109943
[TBL] [Abstract][Full Text] [Related]
23. Topology impacts TRAIL therapy: Differences in primary cancer growth and liver metastasis between orthotopic and subcutaneous xenotransplants of pancreatic ductal adenocarcinoma cells.
Kettler B; Trauzold A; Röder C; Egberts JH; Kalthoff H
Hepatobiliary Pancreat Dis Int; 2021 Jun; 20(3):279-284. PubMed ID: 33947634
[TBL] [Abstract][Full Text] [Related]
24. Apoptotic activity and antitumor efficacy of PEGylated TNF-related apoptosis-inducing ligand (TRAIL) in a Mia Paca-2 cell-xenografted mouse model.
Byeon HJ; Choi SH; Choi JS; Kim TH; Lee ES; Lee KC; Youn YS
Biomed Pharmacother; 2014 Feb; 68(1):65-9. PubMed ID: 24268811
[TBL] [Abstract][Full Text] [Related]
25. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand against pancreatic cancer.
Zhang Z; Huang Y; Newman K; Gu J; Zhang X; Wu H; Zhao M; Xianyu Z; Liu X
Clin Cancer Res; 2009 Aug; 15(16):5154-60. PubMed ID: 19671855
[TBL] [Abstract][Full Text] [Related]
26. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.
Romeo C; Weber MC; Zarei M; DeCicco D; Chand SN; Lobo AD; Winter JM; Sawicki JA; Sachs JN; Meisner-Kober N; Yeo CJ; Vadigepalli R; Tykocinski ML; Brody JR
Mol Cancer Res; 2016 Jul; 14(7):599-611. PubMed ID: 27053682
[TBL] [Abstract][Full Text] [Related]
27. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
Matsuzaki H; Schmied BM; Ulrich A; Standop J; Schneider MB; Batra SK; Picha KS; Pour PM
Clin Cancer Res; 2001 Feb; 7(2):407-14. PubMed ID: 11234897
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
29. NF-κB/RelA controlled A20 limits TRAIL-induced apoptosis in pancreatic cancer.
Geismann C; Hauser C; Grohmann F; Schneeweis C; Bölter N; Gundlach JP; Schneider G; Röcken C; Meinhardt C; Schäfer H; Schreiber S; Arlt A
Cell Death Dis; 2023 Jan; 14(1):3. PubMed ID: 36596765
[TBL] [Abstract][Full Text] [Related]
30. Riproximin's activity depends on gene expression and sensitizes PDAC cells to TRAIL.
Adwan H; Murtaja A; Kadhim Al-Taee K; Pervaiz A; Hielscher T; Berger MR
Cancer Biol Ther; 2014 Sep; 15(9):1185-97. PubMed ID: 24918923
[TBL] [Abstract][Full Text] [Related]
31. A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.
Huang M; Zhu H; Yi C; Yan J; Wei L; Yang X; Chen S; Huang Y
Cancer Chemother Pharmacol; 2018 Nov; 82(5):829-838. PubMed ID: 30167846
[TBL] [Abstract][Full Text] [Related]
32. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing survivin levels.
Lu M; Strohecker A; Chen F; Kwan T; Bosman J; Jordan VC; Cryns VL
Clin Cancer Res; 2008 May; 14(10):3168-76. PubMed ID: 18483385
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis.
Egberts JH; Cloosters V; Noack A; Schniewind B; Thon L; Klose S; Kettler B; von Forstner C; Kneitz C; Tepel J; Adam D; Wajant H; Kalthoff H; Trauzold A
Cancer Res; 2008 Mar; 68(5):1443-50. PubMed ID: 18316608
[TBL] [Abstract][Full Text] [Related]
34. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
35. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
Yuan K; Sun Y; Zhou T; McDonald J; Chen Y
Clin Cancer Res; 2013 Sep; 19(17):4750-9. PubMed ID: 23833311
[TBL] [Abstract][Full Text] [Related]
36. The HSP70 and autophagy inhibitor pifithrin-μ enhances the antitumor effects of TRAIL on human pancreatic cancer.
Monma H; Harashima N; Inao T; Okano S; Tajima Y; Harada M
Mol Cancer Ther; 2013 Apr; 12(4):341-51. PubMed ID: 23371857
[TBL] [Abstract][Full Text] [Related]
37. HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.
Schüler S; Fritsche P; Diersch S; Arlt A; Schmid RM; Saur D; Schneider G
Mol Cancer; 2010 Apr; 9():80. PubMed ID: 20398369
[TBL] [Abstract][Full Text] [Related]
38. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K
Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319
[TBL] [Abstract][Full Text] [Related]
39. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
40. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma.
Röder C; Trauzold A; Kalthoff H
Eur J Cell Biol; 2011; 90(6-7):450-5. PubMed ID: 21129814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
